©2018

LUMAYAS

Investment,
Trading, & Financial Insights

October 12, 2018

On Wednesday, the FDA finally lifted their hold on CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals' (NASDAQ:VRTX) CRISPR-Cas9 US clinical trial for their drug CTX001. The treatment aims to implement gene editing to treat sickle cell disease and if the tria...

Please reload

Recent Posts

Please reload

Archive

Please reload

Tags

Please reload